抗雄激素药物在转移性前列腺癌治疗中的研究进展
摘要
性死亡的原因之一。转移性前列腺癌（Metastatic prostatecancer，mPCa）是严重影响前列腺癌患者预后的重要疾病阶
段；目前，转移性前列腺癌的治疗前景正在不断改变，抗雄激素药物作为一类新型抗前列腺癌药物在转移性前列腺
癌的治疗中具有重要地位。本综述主要对临床常见抗雄激素类药物在转移性前列腺癌治疗中的应用现状及未来研究
方向等进展进行综述。
关键词
全文:
PDF参考
[1]Bergengren, Oskar et al. “2022 Update on Prostate
Cancer Epidemiology and Risk Factors-A Systematic
Review.”European urology vol. 84,2 (2023): 191-206.
doi:10.1016/j.eururo.2023.04.021.
[2]李星，and 曾晓勇.“中国前列腺癌流行病学研究
进展.”肿瘤防治研究，48.01（2021）：98-102.
[3]Kang, Juening et al. “Tumor microenvironment
mechanisms and bone metastatic disease progression of
prostate cancer.”Cancer letters vol. 530 (2022): 156-169.
doi:10.1016/j.canlet.2022.01.015.
[4]董世强，et al.“前列腺癌骨转移的治疗进展及疗
效评价.”肿瘤，39.07（2019）：573-581.
[5]李星，and 曾晓勇.“中国前列腺癌流行病学研究
进展.”肿瘤防治研究，48.01（2021）：98-102.
[6]Swami, Umang et al. “Advanced Prostate Cancer:
Treatment Advances and Future Directions.”Trends in
cancer vol. 6,8 (2020): 702-715. doi:10.1016/j.trecan.
2020.04.010.
[7]Tang, Chad et al. “Contemporary prostate cancer
treatment choices in multidisciplinary clinics referenced
to national trends.”Cancer vol. 126,3 (2020): 506-514.
doi:10.1002/cncr.32570.[8]Wells, Kristina V et al. “Prostate cancer and bone:
clinical presentation and molecular mechanisms.”Endocrinerelated cancer vol. 30,9 e220360. 25 Jul. 2023, doi:10.1530/
ERC-22-0360.
[9]Gebrael, Georges et al. “Advances in the treatment of
metastatic prostate cancer.”Trends in cancer vol. 9,10 (2023):
840-854. doi:10.1016/j.trecan.2023.06.009.
[10]牛向南，and 张雁钢.“晚期前列腺癌内分泌治疗
的研究进展.”现代肿瘤医学，32.05（2024）：973-977.
[11]Sekhoacha, Mamello et al. “Prostate Cancer Review:
Genetics, Diagnosis, Treatment Options, and Alternative
Approaches.”Molecules (Basel, Switzerland) vol. 27,17 5730.
5 Sep. 2022, doi:10.3390/molecules27175730.
[12]Kishan, Amar U et al. “Androgen deprivation
therapy use and duration with definitive radiotherapy for
localised prostate cancer: an individual patient data metaanalysis.”The Lancet. Oncology vol. 23,2 (2022): 304-316.
doi:10.1016/S1470-2045(21)00705-1.
[13]Sternberg, Cora N. “Enzalutamide, an oral androgen
receptor inhibitor for treatment of castration-resistant prostate
cancer.”Future oncology (London, England) vol. 15,13
(2019): 1437-1457. doi:10.2217/fon-2018-0940.
[14]Aurilio, Gaetano et al. “Androgen Receptor
Signaling Pathway in Prostate Cancer: From Genetics to
Clinical Applications.”Cells vol. 9,12 2653. 10 Dec. 2020,
doi:10.3390/cells9122653.
[15]本刊编辑部.“抗雄激素药物治疗去势抵抗型前
列腺癌的机制研究进展.”中国肿瘤临床，43.15（2016）：
667.
[16]上官昌盛，廖泽民，and 张于新.“晚期前列腺
癌的内分泌治疗现状.”中国老年学杂志，22（2008）：
2284-2287.
[17]Sathianathen, Niranjan J et al. “Indirect Comparisons
of Efficacy between Combination Approaches in Metastatic
Hormone-sensitive Prostate Cancer: A Systematic Review
and Network Meta-analysis.”European urology vol. 77,3
(2020): 365-372. doi:10.1016/j.eururo.2019.09.004.
[18]卞晓洁，and 叶定伟.“前列腺癌雄激素剥夺治
疗的新思路——睾酮最大控制临床研究新进展.”中国
癌 症 杂 志，31.12（2021）：1209-1214.doi：10.19401/
j.cnki.1007-3639.2021.12.009.
[19]王前奔，and 吴大勇.“抗雄激素药物治疗去势
抵抗型前列腺癌的机制研究进展.”中国肿瘤临床，42.20
（2015）：1002-1006.
[20]Madan, Ravi A et al. “Flutamide With or Without
PROSTVAC in Non-metastatic Castration Resistant (M0)
Prostate Cancer.”The oncologist vol. 28,7 (2023): 642-e561.
doi:10.1093/oncolo/oyad058.
[21]“Flutamide.”LiverTox: Clinical and Research
Information on Drug-Induced Liver Injury, National Institute of
Diabetes and Digestive and Kidney Diseases, 15 March 2023.
[22]Ueda, Takashi et al. “Apalutamide versus
bicalutamide in combination with androgen deprivation
therapy for metastatic hormone sensitive prostate
cancer.”Scientific reports vol. 14,1 705. 6 Jan. 2024,
doi:10.1038/s41598-024-51389-w.
[23]“Bicalutamide.”LiverTox: Clinical and Research
Information on Drug-Induced Liver Injury, National Institute of
Diabetes and Digestive and Kidney Diseases, 15 March 2023.
[24]Gasperoni, Lorenzo et al. “New-generation
androgen receptor signaling inhibitors (ARSIs) in
metastatic hormone-sensitive prostate cancer (mHSPC):
pharmacokinetics, drug-drug interactions (DDIs), and
clinical impact.”Expert opinion on drug metabolism &
toxicology vol. 20,6 (2024): 491-502. doi:10.1080/17425255
.2024.2353749.
[25]Sternberg, Cora N et al. “Enzalutamide and Survival
in Nonmetastatic, Castration-Resistant Prostate Cancer.”The
New England journal of medicine vol. 382,23 (2020): 2197-
2206. doi:10.1056/NEJMoa2003892.
[26]Armstrong, Andrew J et al. “The Efficacy of
Enzalutamide plus Androgen Deprivation Therapy in
Oligometastatic Hormone-sensitive Prostate Cancer: A Post
Hoc Analysis of ARCHES.”European urology vol. 84,2
(2023): 229-241. doi:10.1016/j.eururo.2023.04.002.
[ 2 7 ] G u l , A n i t a e t a l . “ T r e a t m e n t o f n o n -
metastatic castration-resistant prostate cancer: focus on
apalutamide.”Cancer management and research vol. 11
7253-7262. 1 Aug. 2019, doi:10.2147/CMAR.S165706.
[28]何芳，郝俊旭，and 陈立江.“三种新型雄激素
受体抑制剂的研究进展.”中国新药与临床杂志，40.06
（2021）：411-416.doi：10.14109/j.cnki.xyylc.2021.06.03.[29]薛蔚，et al.“前列腺癌新辅助治疗与辅助治疗
的现状及进展.”北京大学学报（医学版），55.05（2023）：
775-780.doi：10.19723/j.issn.1671-167X.2023.05.002.
[30]Wang, Hanling et al. “Antiandrogen treatment
induces stromal cell reprogramming to promote castration
resistance in prostate cancer.”Cancer cell vol. 41,7 (2023):
1345-1362.e9. doi:10.1016/j.ccell.2023.05.016.
[31]Tree, Alison. “Androgen Deprivation Therapy,
Perseverance, and Greek Mythology.”International journal of
radiation oncology, biology, physics vol. 112,2 (2022): 304-
305. doi:10.1016/j.ijrobp.2021.09.032.
[32]Rebello, Richard J et al. “Prostate cancer.”Nature
reviews. Disease primers vol. 7,1 9. 4 Feb. 2021, doi:10.1038/
s41572-020-00243-0.
[33]Lowrance, William et al. “Updates to Advanced
Prostate Cancer: AUA/SUO Guideline (2023).”The Journal
of urology vol. 209,6 (2023): 1082-1090. doi:10.1097/
JU.0000000000003452.
[34]Swami, Umang et al. “Treatment patterns and
outcomes in patients with nonmetastatic castration-resistant
prostate cancer in the United States.”Future oncology
(London, England) vol. 20,32 (2024): 2467-2480. doi:10.108
0/14796694.2024.2373681.
[35]Yanagisawa, Takafumi et al. “Combination of
docetaxel versus nonsteroidal antiandrogen with androgen
deprivation therapy for high-volume metastatic hormonesensitive prostate cancer: a propensity score-matched
analysis.”World journal of urology vol. 41,8 (2023): 2051-
2062. doi:10.1007/s00345-022-04030-2.
[36]Attard, Gerhardt et al. “Abiraterone acetate and
prednisolone with or without enzalutamide for high-risk
non-metastatic prostate cancer: a meta-analysis of primary
results from two randomised controlled phase 3 trials of
the STAMPEDE platform protocol.”Lancet (London,
England) vol. 399,10323 (2022): 447-460. doi:10.1016/
S0140-6736(21)02437-5.
[37]Armstrong, Andrew J et al. “Improved Survival With
Enzalutamide in Patients With Metastatic Hormone-Sensitive
Prostate Cancer.”Journal of clinical oncology : official journal
of the American Society of Clinical Oncology vol. 40,15
(2022): 1616-1622. doi:10.1200/JCO.22.00193.
[38]Chen, Yanhua et al. “Second generation androgen
receptor antagonists and challenges in prostate cancer
treatment.”Cell death & disease vol. 13,7 632. 21 Jul. 2022,
doi:10.1038/s41419-022-05084-1.
[39]Xie, Jingjing et al. “Targeting androgen receptor
phase separation to overcome antiandrogen resistance.”Nature
chemical biology vol. 18,12 (2022): 1341-1350. doi:10.1038/
s41589-022-01151-y.
[40]Kishan, Amar U et al. “Androgen deprivation
therapy use and duration with definitive radiotherapy for
localised prostate cancer: an individual patient data metaanalysis.”The Lancet. Oncology vol. 23,2 (2022): 304-316.
doi:10.1016/S1470-2045(21)00705-1.
[41]Wasim, Sobia et al. “Complexities of Prostate
Cancer.”International journal of molecular sciences vol.
23,22 14257. 17 Nov. 2022, doi:10.3390/ijms232214257.
[42]Wang, Hanling et al. “Antiandrogen treatment
induces stromal cell reprogramming to promote castration
resistance in prostate cancer.”Cancer cell vol. 41,7 (2023):
1345-1362.e9. doi:10.1016/j.ccell.2023.05.016.
[43]Desai, Kunal et al. “Hormonal Therapy for Prostate
Cancer.”Endocrine reviews vol. 42,3 (2021): 354-373.
doi:10.1210/endrev/bnab002.
Refbacks
- 当前没有refback。
